The global brachytherapy market is projected to grow from USD 1.07 billion in 2025 to approximately USD 1.99 billion by 2034, registering a CAGR of 7.23% during the forecast period. North America dominated the market with a 46% share in 2024, while Asia Pacific is expected to experience the fastest growth. Rising cancer prevalence, technological innovations, and increasing adoption of targeted radiotherapy are key drivers fueling market expansion.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Brachytherapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Brachytherapy Market, by Dosage
8.1.1 High-dose Rate (HDR) Brachytherapy
8.1.1.1. Market Revenue and Forecast
8.1.2. Low-dose Rate (LDR) Brachytherapy
8.1.2.1. Market Revenue and Forecast
9.1. Brachytherapy Market, by Product
9.1.1. Seeds
9.1.1.1. Market Revenue and Forecast
9.1.2. Applicators & Afterloaders
9.1.2.1. Market Revenue and Forecast
9.1.3. Electronic Brachytherapy
9.1.3.1. Market Revenue and Forecast
10.1. Brachytherapy Market, by Application
10.1.1. Prostate Cancer
10.1.1.1. Market Revenue and Forecast
10.1.2. Gynecological Cancer
10.1.2.1. Market Revenue and Forecast
10.1.3. Breast Cancer
10.1.3.1. Market Revenue and Forecast
10.1.4. Others
10.1.4.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Dosage
11.1.2. Market Revenue and Forecast, by Product
11.1.3. Market Revenue and Forecast, by Application
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Dosage
11.1.4.2. Market Revenue and Forecast, by Product
11.1.4.3. Market Revenue and Forecast, by Application
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Dosage
11.1.5.2. Market Revenue and Forecast, by Product
11.1.5.3. Market Revenue and Forecast, by Application
11.2. Europe
11.2.1. Market Revenue and Forecast, by Dosage
11.2.2. Market Revenue and Forecast, by Product
11.2.3. Market Revenue and Forecast, by Application
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Dosage
11.2.4.2. Market Revenue and Forecast, by Product
11.2.4.3. Market Revenue and Forecast, by Application
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Dosage
11.2.5.2. Market Revenue and Forecast, by Product
11.2.5.3. Market Revenue and Forecast, by Application
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Dosage
11.2.6.2. Market Revenue and Forecast, by Product
11.2.6.3. Market Revenue and Forecast, by Application
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Dosage
11.2.7.2. Market Revenue and Forecast, by Product
11.2.7.3. Market Revenue and Forecast, by Application
11.3. APAC
11.3.1. Market Revenue and Forecast, by Dosage
11.3.2. Market Revenue and Forecast, by Product
11.3.3. Market Revenue and Forecast, by Application
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Dosage
11.3.4.2. Market Revenue and Forecast, by Product
11.3.4.3. Market Revenue and Forecast, by Application
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Dosage
11.3.5.2. Market Revenue and Forecast, by Product
11.3.5.3. Market Revenue and Forecast, by Application
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Dosage
11.3.6.2. Market Revenue and Forecast, by Product
11.3.6.3. Market Revenue and Forecast, by Application
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Dosage
11.3.7.2. Market Revenue and Forecast, by Product
11.3.7.3. Market Revenue and Forecast, by Application
11.4. MEA
11.4.1. Market Revenue and Forecast, by Dosage
11.4.2. Market Revenue and Forecast, by Product
11.4.3. Market Revenue and Forecast, by Application
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Dosage
11.4.4.2. Market Revenue and Forecast, by Product
11.4.4.3. Market Revenue and Forecast, by Application
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Dosage
11.4.5.2. Market Revenue and Forecast, by Product
11.4.5.3. Market Revenue and Forecast, by Application
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Dosage
11.4.6.2. Market Revenue and Forecast, by Product
11.4.6.3. Market Revenue and Forecast, by Application
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Dosage
11.4.7.2. Market Revenue and Forecast, by Product
11.4.7.3. Market Revenue and Forecast, by Application
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Dosage
11.5.2. Market Revenue and Forecast, by Product
11.5.3. Market Revenue and Forecast, by Application
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Dosage
11.5.4.2. Market Revenue and Forecast, by Product
11.5.4.3. Market Revenue and Forecast, by Application
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Dosage
11.5.5.2. Market Revenue and Forecast, by Product
11.5.5.3. Market Revenue and Forecast, by Application
12.1. Varian Medical Systems, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Becton
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Dickinson & Company
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Elekta AB
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Isoray Medical, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Eckert & Ziegler BEBIG
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. iCAD, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. CIVCO Medical Solutions
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Theragenics Corporation
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description